Abbott latest victim of FDA’s missed PDUFA dates
Executive Summary
Abbott Laboratories joins the ranks of pharma companies whose PDUFA action dates for NDAs have passed, as FDA told the company this week it needs more time to review its cholesterol drug TriLipix (ABT-335), a next-generation fenofibrate. The agency did not request additional data or extend the drug's PDUFA date. Abbott joins a long list of drug companies affected by the resource-strapped agency (1"The Pink Sheet," Sept. 29, 2008, p. 21). Abbott still expects a fourth quarter approval. It was a rough week for Abbott, as the company also received a complete response letter Oct. 20 from FDA for its NDA for a controlled-release form of hydrocodone with acetaminophen
You may also be interested in...
FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.